| Quarter | Holdings | Value ($000) | Top Holdings | Form Type | Date Filed | Filing ID |
|---|---|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 13F-HR | 8/14/2026 | 000119312526349827 | |
| Q1 2026 | 1 | 0 | 13F-HR | 5/13/2026 | 000119312526221713 | |
| Q4 2025 | 1 | 0 | 13F-HR | 2/12/2026 | 000119312526049427 |
Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each security where the latest filing since 12/18/2024 is a 13D, newest first.
| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||||
|
Arrowhead Pharmaceuticals, Inc.
13D/A
ARWR · 04280A100
|
0% |
8/15/2025
Event 8/13/2025
|
||||
| Sarepta Therapeutics, Inc. | 0% | |||||
| Sarepta Therapeutics Investments, Inc. | 0% | |||||